ALNAQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALNAQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Allena Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Jun. 2022 was -377.41%.
As of today (2024-04-29), Allena Pharmaceuticals's WACC % is 0.00%. Allena Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Allena Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.
The historical data trend for Allena Pharmaceuticals's ROC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allena Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||
ROC % | Get a 7-Day Free Trial | -938.20 | -1,468.96 | -1,484.11 | -848.89 | -685.94 |
Allena Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | |
ROC % | Get a 7-Day Free Trial | -2,444.65 | -2,219.82 | -572.78 | -462.56 | -377.41 |
Allena Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2021 is calculated as:
ROC % (A: Dec. 2021 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (A: Dec. 2020 ) | + | Invested Capital (A: Dec. 2021 )) | / count ) |
= | -47.649 * ( 1 - 0% ) | / | ( (1.973 | + | 11.92) | / 2 ) |
= | -47.649 | / | 6.9465 | |||
= | -685.94 % |
where
Invested Capital | (A: Dec. 2020 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 38.931 | - | 5.831 | - | ( 35.042 | - | max(0, 6.122 | - | 37.249 | + | 35.042 | )) |
= | 1.973 |
Invested Capital | (A: Dec. 2021 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 34.757 | - | 5.51 | - | ( 29.988 | - | max(0, 15.679 | - | 33.006 | + | 29.988 | )) |
= | 11.92 |
Allena Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2022 is calculated as:
ROC % (Q: Jun. 2022 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Mar. 2022 ) | + | Invested Capital (Q: Jun. 2022 )) | / count ) |
= | -27.696 * ( 1 - 0% ) | / | ( (8.068 | + | 6.609) | / 2 ) |
= | -27.696 | / | 7.3385 | |||
= | -377.41 % |
where
Invested Capital | (Q: Mar. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 21.732 | - | 4.769 | - | ( 8.895 | - | max(0, 10.116 | - | 20.197 | + | 8.895 | )) |
= | 8.068 |
Invested Capital | (Q: Jun. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 17.811 | - | 5.141 | - | ( 6.589 | - | max(0, 10.425 | - | 16.486 | + | 6.589 | )) |
= | 6.609 |
Note: The Operating Income data used here is four times the quarterly (Jun. 2022) data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allena Pharmaceuticals (OTCPK:ALNAQ) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Allena Pharmaceuticals's WACC % is 0.00%. Allena Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Allena Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Thank you for viewing the detailed overview of Allena Pharmaceuticals's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Louis Md Brenner | officer: See Remarks | RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02140 |
Mark J. Fitzpatrick | director | 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142 |
Richard D Katz | officer: Chief Financial Officer | 4505 EMPEROR BOULEVARD, SUITE 300, DURHAM NC 27703 |
Edward Wholihan | officer: Chief Financial Officer | C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462 |
Ann Calby Miller | director | C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
Allene M. Diaz | director | C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462 |
Hack Andrew A. F. | director | 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142 |
Bessemer Venture Partners Vii L.p. | 10 percent owner | C/O BESSEMER VENTURE PARTNERS, 1865 PALMER AVENUE, LARCHMONT NY 10538 |
Hbm Biocapital Ii Lp | 10 percent owner | 11-15 SEATON PLACE, ST. HELIER Y9 JE4 0QH |
James N Topper | director, 10 percent owner | 550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301 |
Fhm Vi, L.l.c. | 10 percent owner | 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Robert I Tepper | director, 10 percent owner | 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215 |
Third Rock Ventures Ii, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Robert Alexander | director | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Alexey L Margolin | director, officer: Chief Executive Officer | C/O ALTUS PHARMACEUTICALS INC., 125 SIDNEY STREET, CAMBRIDGE MA 02139 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 07-14-2021
By Don Li2 Don Li2 • 11-10-2021
By PurpleRose PurpleRose • 07-15-2022
By Marketwired Marketwired • 09-29-2021
By PRNewswire PRNewswire • 06-21-2022
By GuruFocusNews GuruFocusNews • 01-04-2022
By Marketwired Marketwired • 07-14-2021
By PRNewswire PRNewswire • 06-01-2022
By PRNewswire PRNewswire • 07-11-2022
By GuruFocusNews GuruFocusNews • 11-15-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.